Synta Pharmaceuticals Corp.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.syntapharma.com
Clinical Trials
40
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
- Conditions
- Non-Small-Cell Lung AdenocarcinomaNon-small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 696
- Registration Number
- NCT01798485
- Locations
- 🇺🇸
Arizona Oncology Associates PC- NAHOA, Flagstaff, Arizona, United States
🇺🇸Arizona Oncology Associates, PC- NAHOA, Prescott Valley, Arizona, United States
🇺🇸Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
- Conditions
- Breast CancerHER-2 Positive Breast CancerER/Progressive Response (PR) + Refractory to Prior Hormonal TreatmentTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 51
- Registration Number
- NCT01677455
- Locations
- 🇬🇧
Synta Pharmaceuticals Investigative Site, Oxford, United Kingdom
🇬🇧Synta Pharmaceutical Investigative Site, Peterborough, United Kingdom
🇰🇷Synta Pharmacuetical Investigative Site, Seoul, Seodaemun-GU, Korea, Republic of
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 12
- Registration Number
- NCT01562015
- Locations
- 🇨🇦
Synta Pharmaceuticals Investigative Site, Toronto, Ontario, Canada
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 385
- Registration Number
- NCT01348126
- Locations
- 🇬🇧
Synta Pharmaceuticals Investigative Site, London, United Kingdom
🇺🇸Synta Pharmaceutials Investigative Site, Boston, Massachusetts, United States
🇧🇦Synta Pharmaceuticals Investgative Site, Sarajevo, Bosnia and Herzegovina
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 36
- Registration Number
- NCT01280786
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- Next